However, the clinical responsiveness to GLP-1 analogues varies among patients with type 2 diabetes mellitus [5], which suggests that genetic factors may be crucial in the pharmacological responsiveness of these patients. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.